Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
You must be a Standard 1 Year member to access this content.
Cooley advised Definitive Healthcare on the deal. Definitive Healthcare (Nasdaq: DH) announced its acquisition of Populi for $52 million in an all-cash transaction. This acquisition furthers Definitive...
You must be a Standard 1 Year member to access this content.
Goodwin and Freshfields advised argenx, while Cooley advised the representatives of the several underwriters on the offering. argenx SE closed its $1.27 billion follow-on offering. On July 19,...
You must be a Standard 1 Year member to access this content.
Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Cooley advised SCYNEXIS on the deal. SCYNEXIS announced its exclusive license agreement with GSK for Brexafemme. The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp...
You must be a Standard 1 Year member to access this content.
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...
You must be a Standard 1 Year member to access this content.
Covington & Burling advised AstraZeneca. Skadden represented Centerview Partners LLC, the exclusive financial advisor to CinCor Pharma Inc. Cooley advised CinCor Pharma. CinCor Pharma Inc. (“CinCor”)...
You must be a Standard 1 Year member to access this content.
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
You must be a Standard 1 Year member to access this content.
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
You must be a Standard 1 Year member to access this content.
Cooley advised Frontline Education, while Davis Polk and Jones Day advised Roper Technologies on the deal. Kirkland & Ellis advised Thoma Bravo. Frontline Education, a leading...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Blueprint Medicines Corporation on the deal while Cooley represented Sixth Street. Blueprint Medicines Corporation (NASDAQ: BPMC) announced its strategic financing collaborations with Sixth...
You must be a Standard 1 Year member to access this content.
